Priapism in Patients Chronic Myeloid Leukemia

Azhari Gani, Muhammad Jailani


The aims of this study are to find out the healing process of Priapism in Patients Chronic Myeloid Leukemia. This study used one case of patient which has some complaint, The patients is man with age 29 years old, The patient complained of an enlarged left stomach since 4 months and became heavy in the last 2 weeks, On vital sign examination, compos mentis awareness was found with blood pressure 110/70 mmHg, pulse 80 times per minute, respiratory rate 20 times per minute and temperature 37oC. On the visual analogue scale (VAS) examination showed a value of 4-6 (moderate pain). The result shows that CML is a hematological malignancy characterized by the Philadelphia chromosome and detected clonal expansion of hematopoietic stem cells from ABL BCR examination on chromosomes 9 and 22 which is characterized by an increase in the number of leukocytes with or without enlargement of the spleen. One of the complications of CML is priapism which occurs due to hyperleukocytosis which causes an increase in the viscosity of the blood and this is a major cause of complications of vascular obstruction. Priapism in CML is classified as low-flow (static / ischemic) caused by venocclusiveness which must be treated immediately to restore blood flow to the cavernous corpora by means of needle aspiration.


priapism; patients; chronic myeloid leukemia

Full Text:



Appleby N, Burke E, Curran T, Neary E, Medicine Y, Marrow B. (2015). Chronic Myeloid Leukaemia : Molecular Abnormalities and Treatment Options. Res Gate;6:45–51.

Besa E, Krishnan K.( 2014). Chronic Myelogenous Leukemia. Medscape;1–9.

Chang M-W, Tang C, Chang S. (2015). Priapism--a rare presentation in chronic myeloid leukemia: case report and review of the literature. Chang Gung Med J [Internet]. 2003;26(4):288–92. Available from:

Ergenc H, Varım C, Karacaer C, Çekdemir D. (2015). Chronic myeloid leukemia presented with priapism : Effective management with prompt leukapheresis. Niger J Clin Pract. 2015;18(6):–7.

Ervie M, Boongaling DC, Mortel SRC, Deala RP. (2015). Priapism as a Rare Presentation of Chronic Myelogenous Leukemia;53(4):1–5.

Farhan S, Anjum F, Fs A, Ka A. Chronic Myeloid Leukemia Presenting with Priapism. Leukemia;3(1):1–5.

Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim D-W, Issaragrisil S, et al. (2016). Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENEST nd trial. Leukemia [Internet].;30(5):1044–54. Available from:

Longo DL.( 2010). Harrison’s Hematology and Oncology. 17th ed. Harrison’s Hematology and Oncology. New York: McGraw Hill.

Minckler MR, Conser E, Figueroa JJ, Scott AJ, Gaither J, Amini R, et al. (2017).Case Report The Semantics of Priapism and the First Sign of Chronic Myeloid Leukemia. Hindawi.;x:1–3.

Ocheni S, Ibegbulam O, Olusina D, Oyekunle A, Durosinmi M. (2010). Chronic Myeloid Leukaemia Presenting as Priapism: A Report of 2 Cases and Review of Literature. J Coll Med;15(2):5–10.

Reksodiputro H, Tadjoedin H, Supandiman I, Acang N, Kar AS, I MB, et al. (2015). Epidemiology Study and Mutation Profile of Patients with Chronic Myeloid Leukemia (CML) in Indonesia. J Blood Disord Transfus;6(3):1–13.

Sholikah TA. (2017). Fusion Gene BCR-ABL : from Etiopathogenesis to The Management of Chronic Myeloid Leukemia. J Kedokt dan Kesehat Indones;8(1):29–37.

Tazi L. (2009). Priapism as the first manifestation of chronic myeloid leukemia. Vol. 29, Annals of Saudi Medicine. p. 412.

Wahyudi SS, Soetojo. Priapismus [Internet]. p. 1–18. Available from:

Yu KP, Hwang WS, Lee WC, Lin JS, Her Twu B. (1985). Priapism in Patients with Chronic Myelodi Leukemia: Report of Two Cases. J Med Sci1.;6(1):87–92.

Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology [Internet]. 2009;2009(1):62–9. Available from:


Article Metrics

Abstract view : 81 times
PDF - 37 times


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.